Pertamina Geothermal Energy corrects IPO proceeds use-of-funds report as of June 30, 2026
Bitget2026/10/08 14:16Pertamina Geothermal Energy issued a correction to its previously filed report on the use of IPO proceeds as of June 30, 2026. Net IPO proceeds totaled IDR 8.77 trillion, with IDR 5.93 trillion reported as used, leaving IDR 2.84 trillion remaining. Remaining funds were placed mainly in deposits at Bank BJB and Bank BRI, with disclosed rates of 4.15%–5%. Reported realized allocations included IDR 3.11 trillion for existing-customer capacity expansion CAPEX, IDR 1.53 trillion for partial Facilities Agreement repayment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PT Pertamina Geothermal Energy Tbk published the original content used to generate this news brief via Indonesia Stock Exchange (IDX) (Ref. ID: 32164887) on October 08, 2026, and is solely responsible for the information contained therein.
- Pertamina Geothermal Energy issued a correction to its previously filed report on the use of IPO proceeds as of June 30, 2026.
- Net IPO proceeds totaled IDR 8.77 trillion, with IDR 5.93 trillion reported as used, leaving IDR 2.84 trillion remaining.
- Remaining funds were placed mainly in deposits at Bank BJB and Bank BRI, with disclosed rates of 4.15%–5%.
- Reported realized allocations included IDR 3.11 trillion for existing-customer capacity expansion CAPEX, IDR 1.53 trillion for partial Facilities Agreement repayment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Crypto prices
More
